First-Line Atezolizumab vs Chemotherapy for PD-L1–Positive Metastatic NSCLC

<p><span data-sheets-value= "{"1":2,"2":"<p>This week, we'll review results of a trial that evaluated first-line anti–PD-L1 therapy vs platinum-based chemotherapy in patients with metastatic lung cancer and high PD-L1 expression. We'll also discuss findings from a study that evaluated whether patients receiving care for advanced cancer based on the recommendations of a molecular tumor board tended to survive longer or experience more time without disease progression.</p><p><b>Coverage of stories discussed this week on ascopost.com:</b><br></p><p><a href=\"https://ascopost.com/news/october-2020/first-line-atezolizumab-vs-chemotherapy-in-pd-l1-positive-metastatic-nsclc/\">First-Line Atezolizumab vs Chemotherapy in PD-L1–Positive Metastatic NSCLC: IMpower110</a></p><p><a href=\"https://ascopost.com/news/october-2020/cancer-therapy-based-on-molecular-tumor-board-recommendations/\">Cancer Therapy Based on Molecular Tumor Board Recommendations: Improvement in Outcomes?</a></p><p>To listen to...